Protagonist Therapeutics Inc (NASDAQ:PTGX) insider David Y. Liu sold 875 shares of the firm’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $20.00, for a total transaction of $17,500.00. Following the sale, the insider now owns 4,697 shares in the company, valued at approximately $93,940. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

David Y. Liu also recently made the following trade(s):

  • On Monday, November 13th, David Y. Liu sold 7,000 shares of Protagonist Therapeutics stock. The shares were sold at an average price of $16.97, for a total transaction of $118,790.00.

Protagonist Therapeutics Inc (NASDAQ PTGX) traded down $0.25 during mid-day trading on Friday, reaching $19.25. 95,820 shares of the company traded hands, compared to its average volume of 84,137. Protagonist Therapeutics Inc has a 52 week low of $8.00 and a 52 week high of $26.36.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings data on Monday, November 6th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.69) by $0.40. The business had revenue of $8.78 million for the quarter. Protagonist Therapeutics had a negative net margin of 54.95% and a negative return on equity of 32.56%. equities analysts expect that Protagonist Therapeutics Inc will post -3.66 EPS for the current year.

PTGX has been the topic of several analyst reports. Zacks Investment Research upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target on the stock in a research report on Friday, August 18th. ValuEngine upgraded shares of Protagonist Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, August 28th. Finally, BMO Capital Markets dropped their price target on shares of Protagonist Therapeutics from $45.00 to $40.00 and set an “outperform” rating on the stock in a research report on Thursday, October 19th.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. California State Teachers Retirement System lifted its holdings in Protagonist Therapeutics by 8.5% during the second quarter. California State Teachers Retirement System now owns 16,600 shares of the company’s stock valued at $188,000 after purchasing an additional 1,300 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Protagonist Therapeutics by 5.7% during the second quarter. Bank of New York Mellon Corp now owns 27,626 shares of the company’s stock valued at $313,000 after purchasing an additional 1,478 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Protagonist Therapeutics by 1.9% during the first quarter. Geode Capital Management LLC now owns 101,218 shares of the company’s stock valued at $1,296,000 after purchasing an additional 1,850 shares in the last quarter. Wells Fargo & Company MN lifted its holdings in Protagonist Therapeutics by 60.8% during the third quarter. Wells Fargo & Company MN now owns 9,565 shares of the company’s stock valued at $169,000 after purchasing an additional 3,617 shares in the last quarter. Finally, TIAA CREF Investment Management LLC lifted its holdings in Protagonist Therapeutics by 19.5% during the second quarter. TIAA CREF Investment Management LLC now owns 23,372 shares of the company’s stock valued at $264,000 after purchasing an additional 3,812 shares in the last quarter. 39.68% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This story was published by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.americanbankingnews.com/2017/12/01/david-y-liu-sells-875-shares-of-protagonist-therapeutics-inc-ptgx-stock.html.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc is a clinical-stage biopharmaceutical company with a peptide technology platform focused on discovering and developing new chemical entities (NECs) to address significant unmet medical needs. The Company’s product pipeline includes PTG-100, PTG-200 and PTG-300. Its primary focus is on developing oral peptide drugs that target biological pathways also targeted by marketed injectable antibody drugs.

Receive News & Ratings for Protagonist Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Protagonist Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.